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Summary
Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced 
non-adipocytic soft-tissue sarcoma. We investigated the eﬀ ect of pazopanib on progression-free survival in patients 
with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Methods This phase 3 study was done in 72 institutions, across 13 countries. Patients with angiogenesis inhibitor-
naive, metastatic soft-tissue sarcoma, progressing despite previous standard chemotherapy, were randomly assigned 
by an interactive voice randomisation system in a 2:1 ratio in permuted blocks (with block sizes of six) to receive either 
pazopanib 800 mg once daily or placebo, with no subsequent cross-over. Patients, investigators who gave the 
treatment, those assessing outcomes, and those who did the analysis were masked to the allocation. The primary 
endpoint was progression-free survival. Eﬃ  cacy analysis was by intention to treat. The trial is registered with 
ClinicalTrials.gov, number NCT00753688.
Findings 372 patients were registered and 369 were randomly assigned to receive pazopanib (n=246) or placebo 
(n=123). Median progression-free survival was 4·6 months (95% CI 3·7–4·8) for pazopanib compared with 
1·6 months (0·9–1·8) for placebo (hazard ratio [HR] 0·31, 95% CI 0·24–0·40; p<0·0001). Overall survival was 
12·5 months (10·6–14·8) with pazopanib versus 10·7 months (8·7–12·8) with placebo (HR 0·86, 0·67–1·11; p=0·25). 
The most common adverse events were fatigue (60 in the placebo group [49%] vs 155 in the pazopanib group [65%]), 
diarrhoea (20 [16%] vs 138 [58%]), nausea (34 [28%] vs 129 [54%]), weight loss (25 [20%] vs 115 [48%]), and hypertension 
(8 [7%] vs 99 [41%]). The median relative dose intensity was 100% for placebo and 96% for pazopanib.




Soft-tissue sarcomas are a group of rare mesenchymal 
cancers that include about 50 histological types, and 
account for 1% of all adult cancers.1,2 The yearly incidence 
of soft-tissue sarcomas in the USA is roughly 11 280 cases, 
with an overall mortality of 3900 deaths per year.3 In 
Europe the estimated yearly incidence is ﬁ ve cases per 
100 000 people.4
The development of new systemic treatments for soft-
tissue sarcomas has progressed little in the past few 
decades, with the exception of treatments for gastro-
intestinal stromal tumours. Patients with metastatic 
soft-tissue sarcomas have a median overall survival of 
about 12 months. The conventional ﬁ rst-line treatment 
for advanced soft-tissue sarcomas other than gastrointes-
tinal stromal tumours is an anthracycline (usually doxo-
rubicin), either as monotherapy or in combination 
with ifosfamide.5 The only truly new treatment approved 
for sarcoma failing standard therapy is trabectedin 
(approved by the European Medicines Agency in 
2007).6,7 Gemcitabine with dacarbazine or docetaxel8–10 
and paclitaxel for angiosarcoma11 seem to improve 
progression-free and overall survival in non-randomised 
and adaptively randomised trials.
Targeted therapies such as imatinib and sunitinib 
have activity for gastrointestinal stromal tumours and 
dermatoﬁ brosarcoma protuberans.12–14 Despite the large 
number of genomic mutations in soft-tissue sarcomas 
no other targeted treatment is eﬀ ective and the role of 
anti-angiogenic treatment is unclear.15–17
Three phase 2 studies have been done to test anti-
angiogenic treatment.18–20 However, until now, no phase 3 
trial has been done. The small-molecule vascular 
endothelial growth factor inhibitor pazopanib—a 
synthetic indazolpyrimidine—is a multitargeted tyrosine 
kinase inhibitor, with activity against vascular endothelial 
growth factors 1, 2, and 3, and platelet-derived growth 
factors.21 Pazopanib is registered for the treatment of 
advanced renal cell cancer.22 In a stratiﬁ ed phase 2 clinical 
trial18 in relapsed or metastatic soft-tissue sarcoma, the 
proportion of patients who were free of progression at 
3 months was 44% for patients with leiomyosarcoma, 
49% for patients with synovial sarcoma, 39% for patients 
with other types of soft-tissue sarcoma, and 26% for 
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patients with adipocytic sarcoma. These data justiﬁ ed 
further inves tigation for soft-tissue sarcoma, along with a 
previous analysis that linked progression-free survival at 
3 months of more than 40% with clinic eﬀ ectiveness.23
On the basis of these data, this trial (PAzopanib 
expLorEd in SofT-Tisue Sarcoma—a phasE 3 study; 
PALETTE) was designed to compare the eﬃ  cacy and 
safety of pazopanib with placebo for soft-tissue sarcoma 
(excluding gastrointestinal stromal tumours and 
adipocytic sarcomas).
Methods
Study design and participants
This multicentre phase 3 study was designed and 
jointly done by the Soft Tissue and Bone Sarcoma 
Group of the European Organisation for Research and 
Treatment of Cancer (EORTC) and GlaxoSmithKline 
between Oct 9, 2008, and Feb 26, 2010. The study 
included patients from 72 institutions worldwide. 
Eligible patients were 18 years or older, with metastatic 
soft-tissue sarcoma and progressive disease according 
to Response Evaluation Criteria In Solid Tumors 
(version 1.0)24 during the 6 months before start of study 
drug or 12 months for previous adjuvant treatment. 
Patients had at least one regimen containing anthra-
cycline and a maximum of four previous lines of 
systemic therapy for metastatic disease (no more than 
two lines of combination regimens).
The most common histological types of soft-tissue 
sarcoma were allowed; excluded were all types of 
adipocytic sarcoma, embryonal rhabdomyosarcoma, 
chondrosarcoma, osteosarcoma, Ewing tumours, primi-
tive neuro ectodermal tumour, gastrointestinal stromal 
tumour, dermatoﬁ brosarcoma protuberans, inﬂ am ma-
tory myo ﬁ broblastic sarcoma, malignant mesothelioma, 
and mixed mesodermal tumours of the uterus. 
Pathology materials (tumour blocks and repre sen tative 
slides) were centrally reviewed. 
Entry criteria included a WHO performance status of 
0 or 1; absence of CNS metastases and leptomeningeal 
metastases; and adequate bone marrow function 
(absolute neutrophil count ≥1·5×10⁹ cells/L, platelets 
≥100×10⁹ per L, haemoglobin ≥9 g/dL), renal function 
(serum creatinine ≤1·5 mg/dL, or, if >1·5 mg/dL, 
calculated creatinine clearance >50 mL/min), hepatic 
function (bilirubin ≤1·5×upper limit of normal, 
aspartate aminotransferase and alanine amino-
transferase ≤2·5×upper limit of normal), and cardiac 
function (based on the institution’s lower limit of 
normal [left ventricular ejection fraction assessed by 
multigated acquisition scan or echocardiogram], normal 
12 lead electrocardiogram [no prolongation of corrected 
QT interval >480 ms] and no history of any of the 
following in the past 6 months: cardiac angioplasty or 
stenting, myocardial infarction, unstable angina, 
coronary artery bypass graft surgery, symptomatic 
peripheral vascular disease class III or IV congestive 
heart failure, as deﬁ ned by the New York Heart 
Association). Blood pressure had to be below 
150/90 mm Hg, spontaneously or controlled with anti-
hypertensive medication. Anticoagulant therapy was 
permitted with stable coagulation tests. Patients with 
recent (within 6 months) thromboembolic events who 
were stable, taking anticoagulating drugs for at least 
6 weeks were eligible. 
Patients who had had a cerebrovascular accident, 
pulmonary embolism, or untreated deep venous 
thrombosis in the past 6 months were ineligible. 
Patients were also excluded if they had had clinically 
signiﬁ cant gastrointestinal disorders in the past 
6 months, active bleeding from any site, major surgery, 
wound healing diﬃ  culties, or trauma within 28 days 
before start of study drug. Previous treatment with 
inhibitors of angiogenesis or vascular endothelial 
growth factor or drugs that target vascular endothelial 
growth factor receptor were not permitted, but previous 
exposure to mammalian target of rapamycin inhibitors 
was allowed. 
The trial was approved by the institutional review 
board of each participating institution and complied 
with good clinical practice guidelines and the 







Male 54 (44%) 99 (40%)
Female 69 (56%) 147 (60%)
WHO performance status
0 56 (46%) 113 (46%)






Low 3 (2%) 24 (10%)
Intermediate 30 (24%) 63 (26%)
High 90 (73%) 159 (65%)
Primary site involved
No 69 (56%) 131 (53%)
Yes 25 (20%) 62 (25%)
Unknown 1 (1%) 3 (1%)
Missing 28 (23%) 50 (20%)
Liver involved
No 77 (63%) 163 (66%)
Yes 37 (30%) 67 (27%)
Missing 9 (7%) 16 (7%)
Data are n (%), unless otherwise stated. *As judged by local investigators. 
Table 1: Baseline characteristics of patients
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Randomisation and masking
Eligible patients were registered with EORTC in an 
online randomised trial access system, and treatments 
were allocated with the GlaxoSmithKline online regis-
tration and medication ordering system. Patients were 
stratiﬁ ed according to number of previous lines of 
systemic therapy for advanced disease (none or one vs 
two or more), and WHO performance status (0 vs 1). 
They were then randomly assigned with an interactive 
voice randomisation service to receive either pazopanib 
800 mg once daily or placebo (2:1), by permuted block 
randomisation (block sizes of six). Patients, investigators 
who gave the treatment, those assessing outcomes, and 
those who did the analysis were masked to the allocation. 
Treatment allocation remained masked until the database 
was locked, and the list of treatment codes was transferred 
to EORTC on March 1, 2011. Progression-free survival 
and objective responses were assessed by masked 
independent radiology review.
Procedures
Study drug was taken orally once daily. Dose modi-
ﬁ cations for adverse events were done according to the 
protocol. Clinical assessments of safety, including 
medical history and physical examination, and laboratory 
assessment, were done at baseline, and week 4, 8, 12, and 
at 8-week intervals thereafter.
Treatment was continued until disease progression 
(according to Response Evaluation Criteria In Solid 
Tumors, version 1.0), unacceptable toxic eﬀ ects, with-
drawal of consent, or death.24 Adverse events were graded 
according to National Cancer Institute Common Toxicity 
Criteria for adverse events (version 3.0). Quality of life 
was assessed with the EORTC QLQ-C30 (version 3) 
questionnaire,25 global health status/quality-of-life score, 
and EQ5D,26 at baseline, and weeks 4, 8, and 12. Quality 
of life will be assessed in full in a separate report.
Post-protocol treatment was given at the discretion of 
patients and their physicians. Unmasking of the study 
treatment occurred at study analysis or at the physician’s 
request, without notiﬁ cation of the study team at EORTC 
or the study sponsor. An independent data monitoring 
committee monitored safety and reviewed the interim 
overall survival data. At disease progression, no crossover 
was permitted. All patients were followed up for survival 
(until death from any cause or withdrawal of consent). 
Serious adverse events were directly reported to the 
GlaxoSmithKline pharmacovigilance database. Cardiac 
dysfunction was deﬁ ned as an absolute decrease of left 
ventricular ejection fraction of 15% or more compared 
with baseline, or a drop of left ventricular ejection fraction 
to 5% below the lower normal limit of the institution, or as 
symptomatic heart failure with any otherwise unexplained 
decrease in left ventricular ejection fraction below the 
lower limit of normal. The primary endpoint was 
progression-free survival; secondary endpoints were 
overall survival, response rate, safety, and quality of life.
Statistical analysis
Progression-free survival was deﬁ ned as time from 
randomisation to either ﬁ rst disease progression (per 
independent radiology review of images) or death from 
any cause. Patients alive at the time of analysis were 
censored at the date of last disease assessment. Overall 
survival was measured from the date of randomisation to 
the date of death (from any cause). The trial was powered 
to detect a 15% diﬀ erence in progression-free survival at 
6 months, from 15% in the control group (based on 
retrospective analysis23 of data from the Soft Tissue and 
Bone Sarcoma Group) to 30% in the pazopanib group 
(based on the EORTC 62043 phase 2 trial18 done in the 
same patient population), corresponding to a hazard 
ratio (HR) of 0·63. 274 events were needed to detect the 
targeted diﬀ erence with 95% power at a 5% signiﬁ cance 
level. The ﬁ nal analysis of the primary endpoint was 
done with a clinical cutoﬀ  date at which at least 
274 patients had disease progression or at least 
195 had died.
The trial provided 90% power at the 5% signiﬁ cance 
level with 279 events to detect a 33% decrease in the 
death HR, corresponding to an increase of median 
overall survival from 8 months to 12 months. An 
interim analysis of overall survival was done at the time 
372 patients registered
369 randomly assigned
123 allocated placebo 246 allocated pazopanib
1 continued placebo 18 continued pazopanib
123 analysed for progression-
free and overall survival
123 included in safety analysis
246 analysed for progression-
free and overall survival
239 included in safety analysis
239 received pazopanib123 received placebo
221 discontinued pazopanib
167 had disease progression
37 had an adverse event
(treatment-related and unrelated)
12 refused further treatment for
reasons unrelated to adverse events
3 intercurrent death
1 had a protocol deviation
1 no full recovery from laparotomy
122 discontinued placebo
118 had disease progression
3 had an adverse event
(treatment-related and unrelated)
1 discontinued for other reasons
7 did not receive the treatment
1 withdrew consent before
randomisation
1 had serious clinical
deterioration
1 screen failure
Figure 1: Trial proﬁ le
Articles
1882 www.thelancet.com   Vol 379   May 19, 2012
of the analysis of the primary endpoint. The signiﬁ cance 
for overall survival was calculated with the Lan and 
DeMets α spending function with O’Brien-Fleming 
stopping rule.
Survival was estimated by the Kaplan-Meier method. 
The treatment groups were compared with a two-sided 
stratiﬁ ed Wald test. All analyses were done in the 
intention-to-treat population.
We did a prognostic factor analysis for progression-free 
survival with a univariate Cox model; signiﬁ cant factors 
were subsequently included in a multivariable Cox 
regression model (p<0·05). For a predictive analysis of 
progression-free survival Cox models were generated 
with the investigated factor, treatment, and their 
interaction, with a signiﬁ cance value of p<0·05.
The main quality-of-life objective was to test that 
patients who received pazopanib had an improved quality 
of life compared with the placebo group. This analysis 
was done by ﬁ tting a linear mixed model with treatment, 
a (linear) time eﬀ ect, and a time-treatment interaction as 
ﬁ xed eﬀ ects, and a patient-speciﬁ c random eﬀ ect, for all 
randomly assigned patients. Score estimates, standard 
errors, the associated CIs, and resulting tests (χ²) were 
obtained from the model, including a general overall 
post-baseline test for no diﬀ erence between the two 
treatment groups at all post-baseline timepoints, by an 
overall F-test statistic. Diﬀ erences of at least 10 points (on 
a 0–100 scale) were classiﬁ ed as the minimum clinically 
meaningful change in a health-related quality-of-life 
(HRQOL) parameter. Because missing data are 
problematic in most HRQOL studies, sensitivity analyses 
were done, investigating the informative drop-out by 
graphical assessment and which variables aﬀ ect 
compliance by linear regression. For the primary HRQOL 
scale, explicit regression imputation was used in which 
imputed values were predicted from a regression model 
that included factors (time, treatment group, sex, age, 
WHO performance score, and number of previous lines 
of systemic treatment for advanced disease) related to a 
missingness mechanism applied to data.
East (version 5) was used to calculate sample size and 
stopping boundaries; all other statistical analyses were 
done with SAS (version 9.2). 
This trial is registered with ClinicalTrial.gov, number 
NCT00753688.
Role of the funding source
Study investigators of both the EORTC and 
GlaxoSmithKline were involved in writing the report and 
in the decision to submit for publication. GlaxoSmithKline 
employees (listed as authors) were involved in study 
design, data collection, interpretation, and analysis, and 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
372 patients with advanced soft-tissue sarcoma entered 
the study. Patients came from 72 sites, in 13 diﬀ erent 
countries: 224 from Europe (60%), 44 from the USA 
(12%), 47 from Japan (13%), 34 from South Korea (9%), 
and 23 from Australia (6%). 167 (45%) patients were from 
EORTC centres.
Table 1 shows demographics and patients’ baseline 
characteristics. The median age was 55 years (IQR 44–64), 
94 (25%) patients had received previous adjuvant or 
neoadjuvant therapy, 342 (93%) had received previous 
systemic therapy for advanced disease, 207 (56%) had 
had two or more lines of treatment, and 78 (21%) had had 
three or more. 364 (99%) had received anthracyclines 
(301 [82%] for advanced disease), 263 (71%) ifosfamide or 
analogues, 127 (34%) gemcitabine, 104 (28%) docetaxel, 
Figure 2: Kaplan-Meier curves for survival
Progression-free (A) and overall (B) survival. 106 patients died or had disease progression in the placebo group, 
168 in the pazopanib group (cutoﬀ  Nov 22, 2010). 95 patients died in the placebo group, 185 in the pazopanib 
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60 (16%) trabectedin, and 57 (15%) dacarbazine. 
Histological review was done for all but seven patients.
Three patients were not assigned to a group (ﬁ gure 1), 
therefore the intention-to-treat population consisted 
of 369 patients. Six of the 369 patients never started 
treatment (one withdrew consent, two had rapid 
progression of disease, three had newly diagnosed 
thromboembolic events) and information was unavail-
able for one patient, who had drug prescribed but died at 
home shortly after randomisation, and no information 
could be obtained. Consequently, the safety population 
consisted of 362 patients.
The median treatment duration was 8·1 weeks (range 
1–52, IQR 4·0–13·6) for placebo and 16·4 weeks (range 
0–79, IQR 6·3–30·0) for pazopanib. The relative dose 
intensity was 100% for placebo and 96% for pazopanib. 
Treatment was interrupted in 11 (9%) patients receiving 
placebo and 118 (49%) receiving pazopanib, dose 
reductions occurred in ﬁ ve (4%) versus 92 (39%). Reasons 
for treatment discontinuation were disease progression in 
118 (96%) patients in the placebo group and 167 (70%) in 
the pazopanib group, and toxic eﬀ ects related to study 
drug in one (1%) patient in the placebo group and 34 (14%) 
in the pazopanib group.
At the time of the primary analysis, with the data cutoﬀ  
date of Nov 22, 2010, median follow-up was 14·6 months 
(IQR 11·3–19·7) in the placebo group and 14·9 months 
(11·0–18·2) in the pazopanib group, and 19 patients were 
still receiving treatment (ﬁ gure 1). Disease progressed in 
274 patients (106 with placebo vs 168 with pazopanib) and 
215 patients had died (78 vs 137). Median progression-free 
survival was longer for pazopanib compared with placebo 
(ﬁ gure 2A). 
Best overall response, as determined by external review, 
was zero of 123 (0%) for placebo and 14 of 246 (6%) for 
pazopanib for partial response; 47 (38%) for placebo and 
164 (67%) for pazopanib for stable disease; and 70 (57%) 
for placebo and 57 (23%) for pazopanib for progression. 
Early death occurred in six (5%) patients taking placebo, 
three (1%) taking pazopanib; eight (3%) patients in the 
pazopanib group could not be assessed. The investigator’s 
response rate was 0 (0%) in the placebo group and 23 
(9%) in the pazopanib group (all partial responses).
In the interim analysis, median overall survival was 
11·9 months (95% CI 10·4–14·7) in the pazopanib group, 
compared with 10·4 months (8·1–12·7) in the placebo 
group (HR 0·83, 95% CI 0·62–1·09; p=0·18). At the ﬁ nal 
analysis of overall survival, with a clinical cutoﬀ  date of 
Oct 24, 2011, six patients were still receiving treatment; 
280 had died. Overall survival did not diﬀ er signiﬁ cantly 
between groups (ﬁ gure 2B).
Potential prognostic factors were ﬁ rst selected by 
univariate analyses with Cox univariate models (table 2); 
signiﬁ cant factors were subsequently included in a 
multivariable Cox model. Favourable prognostic factors 
in patients treated with pazopanib according to the 
multivariable model were a good performance status 
(HR for 0 vs 1 was 0·73, 95% CI 0·54–0·99; p=0·045) and 
low or intermediate tumour grade (HR for I and II vs 
III was 0·63, 0·45–0·87; p=0·006). Predictive analysis 
for histology subtype was done with Cox models with 
interaction terms; the interaction was not signiﬁ cant 
(ﬁ gure 3).
Table 3 shows the main adverse events. The most 
common adverse events with pazopanib were fatigue, 
diarrhoea, nausea, weight loss, and hypertension. Venous 
thromboembolic events occurred in three (2%) patients 
in the placebo group, and 13 (5%) patients in the 
pazopanib group. Pneumothorax occurred in eight (3%) 
patients taking pazopanib and in one (1%) taking placebo.
A drop in left ventricular ejection fraction occurred in 
three patients in the placebo group and in 16 patients in 
the pazopanib group (of which three were symptomatic) 
during or after treatment. At the primary clinical cut-
oﬀ , left ventricular ejection fraction had improved in 
eight patients, of whom, ﬁ ve continued pazopanib and 
three discontinued for other reasons. No follow-up data 
are available for the other patients.
The main reasons for dose reductions were 
hypertension, fatigue, diarrhoea, anorexia, nausea and 
vomiting, hand-foot syndrome, and increased concen-
trations of liver enzyme. Of eight fatal serious adverse 
events in the pazopanib group, one was multiorgan 
























Performance status (0 vs 1) 0·72 (0·53–0·97) 0·0312
Number of lines of previous systemic 
therapy (0–1 vs 2–4)
0·72 (0·53–0·99) 0·0404
Sex (female vs male) 0·80 (0·59–1·09) 0·1529
Age (≤50 years vs >50 years) 0·99 (0·72–1·36) 0·9587
Grade (I–II vs III) 0·61 (0·44–0·86) 0·0041
Histology subtype 0·6129*
Other sarcoma 1·00 ··
Leiomyosarcoma 0·88 (0·63–1·21) ··
Synovial sarcoma 0·82 (0·51–1·32) ··
Locoregional disease (yes vs no) 0·86 (0·62–1·22) 0·4010
Liver metastases (yes vs no) 0·98 (0·68–1·41) 0·9056
*for leiomyosarcoma versus other versus synovial sarcoma. 
Table 2: Prognostic factors for progression-free survival 
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failure that might have been related to the study drug or 
to antibiotics. In the placebo group six fatal serious 
adverse events occurred, unrelated to study drug.
The most relevant laboratory abnormalities for anti-
angiogenic tyrosine kinase inhibitors were increased 
concentrations of liver enzymes (table 4).
Global health and quality-of-life scores did not diﬀ er 
signiﬁ cantly between groups (appendix) although the 
QLQ-C30 showed signiﬁ cant diﬀ erences for diarrhoea, 
loss of appetite, nausea or vomiting, and fatigue, with 
10 point or more worse symptom scores for pazopanib. 
Because data for quality of life were not collected after 
12 weeks, few conclusions can be made about the eﬀ ect 
of pazopanib on quality of life for the entire progression-
free period.
At the data cutoﬀ  of Nov 22, 2010, 350 patients (94%) 
were oﬀ -protocol, of whom 221 received post-protocol 
treatment (appendix). 24 patients (7%) had surgery and 
64 (18%) had radiotherapy. 75 (62%) patients in the 
placebo received chemotherapy versus 103 (45%) in the 
pazopanib group. 17 (14%) versus 22 (10%) received 
targeted therapies.
Discussion
The ﬁ ndings from this phase 3, placebo-controlled trial 
show that pazopanib signiﬁ cantly increased progression-
free survival compared with placebo. Patients included in 
this study had a very poor prognosis, as shown by the low 
median progression-free survival and the high number 
of adverse events in the placebo group. The eligible 
histological types of soft-tissue sarcoma in the study were 
selected on the basis of the results of the previous EORTC 
phase 2 study, which did not show suﬃ  cient beneﬁ t for 
adipocytic soft-tissue sarcoma, although the diﬀ erent 
subtypes of adipocytic sarcomas were not taken into 
account.3,18 With the inclusion of leiomyosarcomas, 
synovial sarcomas, and many other histological types, 
most soft-tissue sarcoma subtypes were included, which 
makes the results relevant for almost all patients with 
soft-tissue sarcoma. This study is unique because it is the 
ﬁ rst placebo-controlled phase 3 trial of a tyrosine kinase 
inhibitor for soft-tissue sarcoma (panel).
The ﬁ nal overall survival analysis did not show a 
signiﬁ cant beneﬁ t for pazopanib, which matches data 
from the interim analysis. In view of the median overall 
survival of 10·7 months in the placebo group, which was 
2·7 months longer than that estimated for the design 
of the trial, the actual power of this study to detect a 
3 month beneﬁ t for overall survival with pazopanib was 
less than 50%. A trial powered (80% power) to detect a 
3 month beneﬁ t, would need a sample size of more than 
750 patients, which was not deemed feasible. Dilution 
might be explained by the long survival compared with 
the time to progression of disease or the post-progression 
therapy that was administered. In this study, post-
progression therapy was given frequently and varied sub-
stantially (possibly because of the diﬀ erent reimbursable 
treatment options in the diﬀ erent participating countries). 
Whether this variability aﬀ ected the ﬁ nal overall survival 
results is unknown, because it applied to both groups.
The range of adverse events was consistent with the 
safety data for pazopanib in patients with renal cell 
cancer, but a higher proportion of all grade adverse events 
occurred in those with soft-tissue sarcoma, particularly 
for fatigue, nausea, anorexia, weight loss, and dysgeusia.22 
High rates of fatigue and weight loss also occurred in the 
placebo group, and the overall quality of life of patients 
treated with pazopanib was not signiﬁ cantly worse than 
that of the patients given placebo.
Newly reported adverse events were venous thrombo-
embolic events, pneumothorax, and cardiotoxicity. The 
incidence of venous thromboembolism was in the same 
range as has been reported in patients with primary and 
relapsed (extremity) sarcomas, therefore the high 
frequency in the pazopanib group might not be related to 
the drug.27 Case series show that the prevalence of 
pneumothorax is roughly 2% in sarcoma patients.28 This 
proportion is much the same as in our study population. 
Whether the treatment eﬀ ect of pazopanib contributed to 
increased pneumothorax because necrosis of peripheral 
pulmonary or pleural metastases in this study population, 
is unknown.28 
Because of anthracycline pretreatment, special atten tion 
was paid to cardiac adverse events. Furthermore, 
cardiotoxicity is a risk with sunitinib,29 which belongs to 
Placebo group (n=123) Pazopanib group (n=239)
All grades Grade 3 Grade 4 All grades Grade 3 Grade 4
Fatigue 60 (49%) 6 (5%) 1 (1%) 155 (65%) 30 (13%) 1 (<1%)
Diarrhoea 20 (16%) 1 (1%) 0 138 (58%) 11 (5%) 0
Nausea 34 (28%) 2 (2%) 0 129 (54%) 8 (3%) 0
Weight loss 25 (20%) 0 0 115 (48%) 0 0
Hypertension 8 (7%) 4 (3%) 0 99 (41%) 16 (7%) 0
Anorexia 24 (20%) 0 0 95 (40%) 14 (6%) 0
Hair hypopigmentation 3 (2%) 0 0 92 (38%) 0 0
Vomiting 14 (11%) 1 (1%) 0 80 (33%) 8 (3%) 0
Dysgeusia 5 (4%) 0 0 64 (27%) 0 0
Rash or desquamation 13 (11%) 0 0 43 (18%) 1 (<1%) 0
Mucositis 4 (3%) 0 0 29 (12%) 3 (1%) 0
Data are n (%).
Table 3: Common adverse events
Placebo (n=123) Pazopanib (n=239)
γ glutamyl transpeptidase 13 (11%) 30 (13%)
Alanine aminotransferase 4 (3%) 23 (10%)
Aspartate aminotransferase 2 (2%) 19 (8%)
Total bilirubin 2 (2%) 4 (2%)
Data are n (%).
Table 4: Patients with increased concentrations of liver enzymes
See Online for appendix
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the same class of vascular endothelial growth factor 
receptor and platelet-derived growth factor receptor 
inhibitors as pazopanib. The decrease in left ventricular 
ejection fraction was mainly asymptomatic and reversible 
in patients who had adequate follow-up. Timely treatment 
of hypertension for patients receiving antiangiogenic 
treatment should be a standard part of clinical practice, 
because hypertension increases the risk of cardiotoxicity.30 
Anthracycline cardiotoxicity has been studied in detail and 
the eﬀ ect of angiogenesis inhibitors in patients with 
sarcoma is worth investigating, not only for the adult soft-
tissue sarcoma population, but also for the assessment of 
future antiangiogenic therapies in children with sarcoma.31
One limitation of this study is the absence of quality-of-
life data after the ﬁ rst 12 weeks. Knowledge about the 
eﬀ ect of longer use of pazopanib on quality of life 
compared with the placebo group could have provided 
better insight into the clinical meaningfulness of the 
3 months prolongation of progression-free survival. A 
second limitation is that although patients would have 
had, in addition to anthracyclines, all systemic treatments 
available for progressive metastatic disease in their 
country, they might not have received them, since more 
than 50% of patients received post-protocol chemo-
therapy. The patient’s preference for an oral drug might 
have had a role in their decision to enter the study. This 
factor might have diluted the eﬀ ect on overall survival 
more than was expected.
Panel: Research in context
Systematic review
We searched PubMed with the terms “vascular endothelial 
growth factor receptor”, “angiogenesis inhibitor”, and 
“soft tissue sarcoma”, for clinical trials of advanced 
non-gastrointestinal stromal tumour soft-tissue sarcomas 
and for speciﬁ c targeted agents (pazopanib, sunitinib, and 
sorafenib). we included reports in English, published up to 
March 5, 2012. No randomised phase 3 trials comparing a 
multitargeted kinase inhibitor with placebo in 
non-gastrointestinal stromal tumour soft-tissue sarcoma 
have been reported.
Interpretation
To date, this trial is the only placebo-controlled phase 3 study 
done in non-gastrointestinal stromal tumour soft-tissue 
sarcoma, and is the only randomised phase 3 study of 
treatment after second-line therapy. Our results show that 
pazopanib signiﬁ cantly increases progression-free survival by a 
median of 3 months compared with placebo, showing the 
activity of pazopanib after second-line treatment. This study is 
the only randomised phase 3 study of soft-tissue sarcoma that 
shows improvement in progression-free survival. On the basis 
of these results, pazopanib is a new oral treatment option, after 
previous chemotherapy, for metastatic non-gastrointestinal 
stromal tumour, non-adipocytic soft-tissue sarcoma.
Although the exact mechanism by which pazopanib 
aﬀ ects soft-tissue sarcoma is unknown, progression-free 
survival improved in patients of all ages, for most 
histological subgroups (leiomyosarcoma, synovial sar-
coma, and others), and after one or more lines of previous 
systemic treatment.
Pazopanib is an active drug for patients in the 
heterogeneous group of non-adipocytic soft-tissue 
sarcomas. After the breakthroughs of imatinib and 
sunitinib for gastrointestinal stromal tumour, pazopanib 
is the ﬁ rst active oral agent for patients with non- 
gastrointestinal stromal tumour soft-tissue sarcomas 
and is a meaningful addition to the treatment arma-
mentarium for patients with this rare group of tumours.
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